Russian officials either took a massive gamble or had access to early data when they began vaccinating their citizens in December. But this was a gamble that appeared to have paid off when the researchers behind Sputnik, named after the satellite that Moscow sent into orbit in a world-first in 1957, published promising phase three results in February.
The results published in the peer-reviewed Lancet – based on a trial of 14,964 people who had the vaccine and 4,902 who had a placebo – show that the jab is 91.6 per cent effective at preventing infection. This compares to around 70 per cent for the AstraZeneca jab and 95 per cent for the Pfizer shot.
Watch the video with The Telegraph’s Global Health Security Deputy Editor to hear her answer questions about the vaccine’s safety, where it is used around the world and whether it might be used in the UK.